nach oben

Erschienen in:

13.03.2017 | Letter to the Editor

Reply: Methotrexate neurotoxicity due to drug interactions: an inadequate folinic acid effect

verfasst von: Victoria J. Forster, Frederik W. van Delft, Susan F. Baird, Shona Mair, Roderick Skinner, Christina Halsey

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Excerpt

We thank Professor Cohen for his reply and his interesting points regarding the possible role of inadequate folinic acid rescue in contributing to neurotoxic side-effects of methotrexate. We can confirm that the patient reported in our article [1] had not received any previous exposure to any systemic methotrexate (oral or intravenous) even at low dose. In addition, the other published article on this possible interaction with nitrous oxide [2] reported a patient developing symptoms early during induction therapy on a protocol with a standard 3-drug induction (vincristine, asparaginase and corticosteroids). Therefore, concomitant systemic methotrexate appears not to be a contributing factor in either of these reported cases. …

Forster VJ, van Delft FW, Baird SF, Mair S, Skinner R, Halsey C (2016) Drug interactions may be important risk factors for methotrexate neurotoxicity, particularly in pediatric leukemia patients. Cancer Chemother Pharmacol 78(5):1093–1096CrossRefPubMedPubMedCentral

Lobel U, Trah J, Escherich G (2015) Severe neurotoxicity following intrathecal methotrexate with nitrous oxide sedation in a child with acute lymphoblastic leukemia. Pediatr Blood Cancer 62(3):539–541CrossRefPubMed

Krull KR, Cheung YT, Liu W et al (2016) Chemotherapy pharmacodynamics and neuroimaging and neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia. J Clin Oncol 34(22):2644–2653CrossRefPubMedPubMedCentral

Cohen IJ (2014) Inadequate folinic acid rescue after methotrexate causing neurocognitive and neuroradiological central nervous system late effects in children with acute lymphatic leukemia. J Pediatr Hematol Oncol 36(6):501CrossRefPubMed

Cohen IJ (2013) Challenging the clinical relevance of folinic acid over rescue after high dose methotrexate (HDMTX). Med Hypotheses 81(5):942–947CrossRefPubMed

Skarby TV, Anderson H, Heldrup J et al (2006) High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia. Leukemia 20(11):1955–1962CrossRefPubMed

Borsi JD, Sagen E, Romslo I, Moe PJ (1990) Rescue after intermediate and high-dose methotrexate: background, rationale, and current practice. Pediatr Hematol Oncol 7(4):347–363CrossRefPubMed

Eger EI 2nd (1985) Nitrous oxide/N₂O. Elsevier, New York

Cole PD, Beckwith KA, Vijayanathan V, Roychowdhury S, Smith AK, Kamen BA (2009) Folate homeostasis in cerebrospinal fluid during therapy for acute lymphoblastic leukemia. Pediatr Neurol 40(1):34–41CrossRefPubMed

Titel: Reply: Methotrexate neurotoxicity due to drug interactions: an inadequate folinic acid effect
verfasst von: Victoria J. Forster
Frederik W. van Delft
Susan F. Baird
Shona Mair
Roderick Skinner
Christina Halsey
Publikationsdatum: 13.03.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 4/2017
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-017-3270-4

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Reply: Methotrexate neurotoxicity due to drug interactions: an inadequate folinic acid effect

Excerpt

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2017

Cooperative inhibitory effects of uremic toxins and other serum components on OATP1B1-mediated transport of SN-38

An apparent clinical pharmacokinetic drug–drug interaction between bevacizumab and the anti-placental growth factor monoclonal antibody RO5323441 via a target-trapping mechanism

Prognostic impact of normalization of serum tumor markers following neoadjuvant chemotherapy in patients with borderline resectable pancreatic carcinoma with arterial contact

In vitro and in vivo evaluation of dasatinib and imatinib on physiological parameters of pulmonary arterial hypertension

The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer

Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie